2019

Karsch L, Beyreuther E, Passos DE, Pawelke J, Löck S (2019)
Analysing Tumour Growth Delay Data from Animal Irradiation Experiments with Deviations from the Prescribed Dose
Cancers 11: 1281.

Stölzel F, Lüer T, Löck S, Parmentier S, Kuithan F, Kramer M, Alakel NS, Sockel K, Taube F, Middeke JM, Schetelig J, Röllig C, Paulus T, Kotzerke J, Ehninger G, Bornhäuser M, Schaich M, Zoephel K (2019)
The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the Prospective PETAML Trial
Haematologica, published online.

Rassamegevanon T, Löck S, Baumann M, Krause M, von Neubeck C (2019)
Comparable radiation response of ex vivo and in vivo irradiated tumor samples determined by residual γH2AX
Radiother Oncol, in press.

Hoberück S, Michler E, Wunderlich G, Löck S, Hölscher T, Froehner M, Braune A, Platzek I, Seppelt D, Zöphel K, Kotzerke J (2019)
68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients
Nuklearmedizin, published online.

Eulitz J, Troost EGC, Raschke F, Schulz E, Lutz B, Dutz A, Löck S, Wohlfahrt P, Enghardt W, Karpowitz C, Krause M, Lühr A (2019)
Predicting late magnetic resonance image changes in glioma patients after proton therapy
Acta Oncologica, published online.

Zwanenburg A (2019)
Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis
Eur J Nucl Med Mol Imaging, published online.

Meneceur S, Löck S, Gudziol V, Hering S, Bütof R, Rehm M, Baumann M, Krause M, von Neubeck C (2019)
Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens
Radiother Oncol 137: 24-31.

Richter C, Andronesi OC, Borra RJH, Voigt F, Löck S, Dudaa DG, Guimaraes AR, Hong TS, Bortfeld TR, Seco J (2019)
Inter-patient variations of radiation-induced normal-tissue changes in Gd-EOB-DTPA-enhanced hepatic MRI scans during fractionated proton therapy
Clin Transl Radiat Oncol 18:113-119.

Kohler A, Löck S, Appold S, Bandurska-Luque A, Hoberück S, Schreiber A, Kotzerke J, Zips D, Zöphel K (2019)
Comparison of subjective evaluation versus objective algorithm in the interpretation of follow-up FDG-PET/CT scans after radiochemotherapy in head and neck cancer patients
Nuklearmedizin 58: 93-100.

Dutz A, Agolli L, Baumann M, Troost EGC, Krause M, Hölscher T, Löck S (2019)
Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis
Acto Onologica 58: 916-925.

Linge A, Schmidt S, Lohaus F, Krenn C, Bandurska-Luque A, Platzek I, von Neubeck C, Appold S, Nowak A, Gudziol V, Buchholz F, Baretton GB, Baumann M, Löck S, Krause M (2019)
Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy
Clin Transl Radiat Oncol 16: 40-47.

Löck S, Linge A, Seidlitz A, Bandurska-Luque A, Nowak A, Gudziol V, Buchholz F, Aust DE,  Baretton GB, Zöphel K, Steinbach J, Kotzerke J, Overgaard J, Zips D, Krause M, Baumann M, Troost EGC (2019)
Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy
Radiother Oncol 135: 43-50.

Pfaehler E, Zwanenburg A, de Jong JR, Boellaard R (2019)
RaCaT: An open source and easy to use radiomics calculator tool
PLoS ONE 14: e0212223.

Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Perrin R, Appold S, Krause M, Steinbach J, Kotzerke J, Hofheinz F, Zips D, Baumann M, Troost EGC (2019)
Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients
Clin Transl Radiat Oncol 15: 108-112.

Rauschenberg R, Bruns J, Brütting J, Daubnerd D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel JC, Berking C, Kaehler KC, Utikal J, Gutzmer R, Terheyden P, Meiss F, Rafei-Shamsabadi D, Kiecker F, Debus D, Dabrowski E, Arnold A, Garzarolli M, Kuske M, Beissert S, Löck S, Linn J, Troost EGC, Meier F (2019)
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases
Eur J Cancer 110: 11-20.

Zwanenburg A, Leger S, Agolli L, Pilz K, Troost EGC, Richter C, Löck S (2019)
Assessing robustness of radiomic features by image perturbation
Scientific Reports 9: 614.

Digomann D, Kurth I, Tyutyunnykova A, Chen O, Löck S, Gorodetska I, Peitzsch C, Skvortsova I, Negro G, Aschenbrenner B, Eisenhofer G, Richter S, Heiden S, Porrmann J, Klink B, Schwager C, Dowle AA, Hein L, Kunz-Schughart LA, Abdollahi A, Lohaus F, Krause M, Baumann M, Linge A, Dubrovska A (2019)
The CD98 heavy chain is a marker and regulator of head and neck squamous cell carcinoma radiosensitivity
Clin Cancer Res, published online.

Wink K, Löck S, Rossi M, Baardwijk A, Belderbos J, Ruysscher D, Troost E (2019)
Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer

Radiother Oncol 131: 120-126.

Dutz A, Löck S (2019)
Competing risks in survival data analysis
Radiother Oncol 130: 185-189.

Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Abolmaali N, Seidlitz A, Appold S,  Krause M, Steinbach J, Kotzerke J, Zips D, Baumann M, Troost EGC (2019)
FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients
Radiother Oncol 130: 97-103.

Leger S, Zwanenburg A, Pilz K, Zschaeck S, Zöphel K, Kotzerke J, Schreiber A, Zips D, Krause M, Baumann M, Troost EGC, Richter C, Löck S (2019)
CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer
Radiother Oncol 130: 10-17.

Dutz A, Lühr A, Agolli L, Troost EGC, Krause M, Baumann M, Vermeren X, Geismar D, Schapira EF, Bussière M, Daly JE, Bussière MR, Timmermann B, Shih HA, Löck S (2019)
Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours
Radiother Oncol 130: 164-171.

Lohaus F, Zöphel K, Löck S, Wirth M, Kotzerke J, Krause M, Baumann M, Troost E, Hölscher T (2019)
Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Eur Urol 75: 548-551.

Aktar R, Dietrich A, Tillner F, Kotb S, Löck S, Willers H, Baumann M, Krause M, Bütof R (2019)
Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios
Br J Radiol 92: 20180539.

2018

Cordes N, Ney M, Beleites T, Aust D, Baretton G, Thames H, Baumann M, Krause M, Löck S, Appold S (2018)
Retrospective investigation of the prognostic value of the β1 integrin expression in patients with head and neck squamous cell carcinoma receiving primary radio(chemo)therapy
PLoS ONE 13: e0209479.

Rassamegevanon T, Löck S, Baumann M, Krause M, von Neubeck C (2018)
Heterogeneity of γH2AX Foci Increases in Ex Vivo Biopsies Relative to In Vivo Tumors.
Int J Mol Sci 19: 2616.

Dutz A, Troost EGC, Löck S (2018)
Keine Überlegenheit der Protonentherapie gegenüber der IMRT beim lokal fortgeschrittenen NSCLC
Strahlenther Onkol 194: 790-793.

Dutz A, Troost EGC, Löck S (2018)
Keine Überlegenheit gegenüber der IMRT
InFo Onkologie 21: 22-24.

Zwanenburg A, Löck S (2018)
Why validation of prognostic models matters?

Radiother Oncol 127: 370-373.

Schmidt S, Linge A, Zwanenburg A, Leger S, Lohaus F, Krenn C, Appold S, Gudziol V, Nowak A, von Neubeck C, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch SU, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S (2018)
Development and validation of a gene signature for patients with head and neck squamous cell carcinomas treated by postoperative radio(chemo)therapy

Clin Cancer Res 24: 1367-1374.

Linge A, Schötz U, Löck S, Lohaus F, von Neubeck C, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Lauber K, Pigorsch A, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Krause M, Belka C, Baumann M (2018)
Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC

Radiother Oncol 127: 27-35.

Vallières M, Zwanenburg A, Badic B, Cheze‐Le Rest C, Visvikis D, Hatt M (2018)
Responsible Radiomics Research for Faster Clinical Translation
J Nucl Med 59: 189-193.

Hinrichs CN, Ingargiola M, Käubler T, Löck S, Temme A, Köhn-Luque A, Deutsch A, Vovk O, Stasyk O, Kunz-Schughart LA (2018)
Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization

Mol Cancer Ther 17: 393-406.

2017

Bütof R, Simon M, Löck S, Troost EGC, Appold S, Krause M, Baumann M (2017)
PORTAF–postoperative radiotherapy of non-small cell lung cancer: accelerated versus conventional fractionation–study protocol for a randomized controlled trial

Trials 18: 608.

Leger S, Löck S, Hietschold V, Haase R, Böhme HJ, Abolmaali N (2017)
Physical correction model for automatic correction of intensity non-uniformity in magnetic resonance imaging
Phys Imag Rad Oncol 4: 32-38.

Cubillos-Mesías M, Bauman M, Troost EGC, Löck S, Richter C, Stützer K (2017)
Impact of robust treatment planning on single- and multi-field optimized plans for proton beam therapy of unilateral head and neck target volumes

Radiation Oncology 12: 190.

Bütof R, Gumina C, Valentinia C, Sommerer A, Appold S, Zips D, Löck S, Baumann M, Troost EGC (2017)
Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy
Clin Transl Radiat Oncol 7: 36-42.

Leger S, Zwanenburg A, Pilz K, Lohaus F, Linge A, Zöphel K, Kotzerke J, Schreiber A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Krause M, Baumann M, Troost EGC, Löck S, Richter C (2017)
A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling
Scientific Reports 7: 13206.

Stützer K, Jakobi A, Bandurska-Luque A, Barczyk S, Arnsmeyer C, Löck S, Richter C (2017)
Potential proton and photon dose degradation in advanced head and neck cancer patients by intratherapy changes

J Appl Clin Med Phys 18: 104-113.

Löck S, Perrin R, Seidlitz A, Bandurska-Luque A, Zschaeck S, Zöphel K, Krause M, Steinbach J, Kotzerke J, Zips D, Troost EGC, Baumann M (2017)
Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging

Radiother Oncol 124: 533-540.

Koi L, Löck S, Linge A, Thurow C, Hering S, Baumann M, Krause M, Gurtner K (2017)
EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models

Radiother Oncol 124: 496-503.

Lühr A, Löck S, Jakobi A, Stützer K, Bandurska-Luque A, Vogelius IR, Enghardt W, Baumann M, Krause M (2017)
Modeling tumor control probability for spatially inhomogeneous risk of failure based on clinical outcome data
Z Med Phys 27: 285-299.

Rassamegevanon T, Löck S, Range U, Krause M, Baumann M, von Neubeck C (2017)
Tumor heterogeneity determined with a γH2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models
Radiother Oncol 124: 379-385.

Zschaeck S, Hofheinz F, Zöphel K, Bütof R, Jentsch C, Schmollack J, Löck S, Kotzerke J, Baretton G, Weitz J,  Baumann M, Krause M (2017)
Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy

Eur J Nucl Med Mol Imaging 44: 1813-1822.

Zschaeck S, Löck S, Leger S, Haase, R Bandurska-Luque A, Appold S, Kotzerke J, Zips D, Richter C, Gudziol V, Schreiber A, Zöphel K, Baumann M, Krause M (2017)
FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy

Radiother Oncol 122: 437-444.

Tomkovič J, Muessel W, Strobel H, Löck S, Schlagheck P, Ketzmerick R, Oberthaler MK (2017)
Experimental observation of the Poincaré-Birkhoff scenario in a driven many-body quantum system
Phys Rev A 95: 011602(R).

Liebscher S, Koi L, Löck S, Muders MH, Krause M (2017)
The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo

Clin Transl Radiat Oncol 2: 7-12.

2016

Linge A, Löck S, Krenn C, Appold S, Lohaus F, Nowak A, Gudziol V, Baretton GB, Buchholz F, Baumann M, Krause M (2016)
Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy

Clin Transl Radiat Oncol 1: 19-26.

Zwanenburg A, Leger A, Vallières M, Löck S (2016)
Image biomarker standardisation initiative - feature definitions

arXiv:1612.07003 [cs.CV].

Linge A, Lohaus F, Löck S, Nowak A, Gudziol V, Valentini C, von Neubeck C, Jütz M, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Ganswindt U,  Belka C, Pigorsch S,  Combs SE, Mönnich D, Zips D, Buchholz F, Aust DE, Baretton GB, Thames HD, Dubrovska A, Alsner J, Overgaard J, Krause M, Baumann M (2016)
HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)

Radiother Oncol 121: 364-373.

Zschaeck S, Simon M, Löck S, Troost ET, Stützer K, Wohlfahrt P, Appold S, Makocki S, Bütof R, Richter C, Baumann M, Krause M (2016)
PRONTOX – proton therapy to reduce acute normal tissue toxicity in locally
advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial

Trials 17: 543.

Kurlishchuk Y, Vynnytska-Myronovska B, Grosse-Gehling P, Bobak Y, Manig F, Chen O, Merker SR, Henle T, Löck S, Stange DE, Stasyk O, Kunz-Schughart LA (2016)
Co-application of canavanine and irradiation uncouples anticancer potential of arginine deprivation from citrulline availability

Oncotarget 7: 73292-73308.

Jentsch C, Bergmann R, Brüchner K, Mosch B, Yaromina A, Krause M, Zips D, Troost EG, Löck S, Kotzerke J,  Steinbach J, Thames H, Baumann M, Beuthien-Baumann B (2016)
Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours
Radiother Onco 121: 447-452.

Stützer K, Haase R, Lohaus F, Barczyk S, Exner F, Löck S, Rühaak J, Lassen-Schmidt B, Corr D and Richter C (2016)
Evaluation of a deformable registration algorithm for subsequent lung computed tomography imaging during radiochemotherapy

Med Phys 43: 5028-5039.

Linge A, Lohaus F, Löck S, Krause M, Baumann M (2016)
Biomarker für die individualisierte Strahlentherapie

Nova Acta Leopoldina NF 121: 333-344.

Tillner F, Thute P, Löck S, Dietrich A, Fursov A, Haase R, Lukas M, Rimarzig B, Sobiella M, Krause M, Baumann M, Bütof R, Enghardt W (2016)
Precise image-guided irradiation of small animals: a flexible non-profit platform
Phys Med Biol 61: 3084.

Linge A, Löck S, Gudziol V, Nowak A, Lohaus F, von Neubeck C, Jütz M, Abdollahi A, Debus J, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Avlar M, Grosu AL, Bayer C, Belka C, Pigorsch S,  Combs SE, Welz S, Zips D, Buchholz F, Aust DE, Baretton GB, Thames H, Dubrovska A, Alsner J, Overgaard J, Baumann M, Krause M (2016)
Low CSC marker expression and low hypoxia identify good prognosis subgroups in HPV(-)HNSCC after postoperative radiochemotherapy: a multicenter study of the DKTK-ROG

Clin Cancer Res 22: 2639-49

2015

Jakobi A, Lühr A, Stützer K, Bandurska-Luque A, Löck S, Krause M, Baumann M, Perrin R, Richter C (2015)
Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy
Front Oncol 5: 256.

Jakobi A, Stützer K, Bandurska-Luque A, Löck S, Haase R, Wack LJ, Mönnich D, Thorwarth D, Perez D, Lühr A, Zips D, Krause M, Baumann M, Perrin R, Richter C (2015)
NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy

Acta Oncol 54: 1558-1664.

Gehler S, Löck S, Shinohara S, Bäcker A, Ketzmerick R, Kuhl U, Stöckmann HJ (2015)
Experimental Observation of Resonance-Assisted Tunneling

Phys Rev Lett 115: 104101.

Seidlitz A, Siepmann T, Löck S, Juratli T, Baumann M, Krause M (2015)
Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme
Radiat Oncol 10: 172.

Bütof R, Hofheinz F, Zöphel K, Stadelmann T, Schmollack J, Jentsch C, Löck S, Kotzerke J, Baumann M, van den Hoff J (2015)
Prognostic value of pretherapeutic tumor-to-blood standard uptake ratio (SUR) in patients with esophageal carcinoma

J Nucl Med 56: 1150-1156.

Jakobi A, Bandurska-Luque A, Stützer K, Haase R, Löck S, Wack LJ, Mönnich D, Thorwarth D, Perez D, Lühr A,  Zips D, Krause M, Baumann M, Perrin R, Richter C (2015)
Identification of patient benefit from proton therapy for advanced head and neck cancer patients based on individual and subgroup NTCP analysis

Int J Radiat Oncol Biol Phys 92: 1165–1174.

Löck S, Roth K, Skripcak T, Worbs M, Helmbrecht S, Jakobi A, Just U, Krause M, Baumann M, Enghardt W, Lühr A (2015)
Implementation of a software for REmote COMparison of PARticlE and photon treatment plans: ReCompare
Z Med Phys 25: 287-294.

2014

Lohaus F, Linge A, Tinhofer I, Budach V, Gkika E, Stuschke M, Balermpas P, Rödel C, Avlar M, Grosu A, Abdollahi A, Debus J, Bayer C, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, von Neubeck C, Baretton GB, Löck S, Thames HD, Krause M, Baumann M (2014)
HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma:Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
Radiother Oncol 113: 317.

Lühr A, Löck S, Roth K, Helmbrecht S, Jakobi A, Petersen JB, Just U, Krause M, Enghardt W, Baumann M (2015)
Concept for individualized patient allocation: ReCompare-remote comparison of particle and photon treatment plans

Radiat Oncol 9: 59.

Bütof R, Kirchner K, Appold S, Löck S, Rolle A, Höffken G, Krause M, Baumann M (2014)
Potential clinical predictors of outcome after postoperative radiotherapy of non-small cell lung cancer

Strahlenther Onkol 190: 263–269.